Tinzaparin - Clinical Resources

Transitioning to Tinzaparin - Effective September 27, 2022

• All SHA sites transitioned to using tinzaparin as the low molecular weight heparin (LMWH) for most indications. Simultaneously, there was a switch to using enoxaparin REDESCA (a biosimilar agent) for the remaining indications.

Learning Module - Transitioning to Tinzaparin

• Learning Modules Online Access Instructions - Search by Title

  • Transition to Tinzaparin - A Provincial Approach

ALERT:  Log in to MyConnection prior to accessing any learning module to ensure completion is recorded in the system.

Tinzaparin in Hemodialysis

Clinical Procedure

• Circuit Anticoagulation in Hemodialysis (CS-CP-0074)